Learning from our Mistakes: Equipping Nations to Meet Biological Diversity Goals
January 28, 2021 09:10 ET | NatureServe
Washington, DC, Jan. 28, 2021 (GLOBE NEWSWIRE) -- NatureServe’s Director of Biodiversity Indicators Program, Mike Gill, collaborated with researchers from China and Germany to complete a pivotal...
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
January 07, 2021 14:15 ET | BioNTech SE
Collaborative study of BioNTech with TRON and the University Medical Center and Research Center for Immunotherapy at Johannes Gutenberg University of Mainz introduces novel non-inflammatory mRNA...
BioNTech veröffentlicht Daten zu neuartigem mRNA-Impfstoffansatz gegen Autoimmunkrankheiten in Science
January 07, 2021 14:15 ET | BioNTech SE
Gemeinsame Studie von BioNTech, TRON und der Universitätsmedizin sowie dem Forschungszentrum für Immuntherapie der Johannes Gutenberg-Universität Mainz untersucht neuartigen entzündungshemmenden...
logo_new_alexis_withTag_withTMTM_72dpi_0 (002).jpg
Livanta Wins Highest Honor in 2020 MarCom Awards
October 28, 2020 16:00 ET | Livanta LLC
ANNAPOLIS JUNCTION, Md., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Livanta LLC announced today that the firm has been recognized internationally for excellence in the development of communications products...
Cyclacel Pharmaceuticals logo
Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer
July 13, 2020 07:00 ET | Cyclacel
-- Characterization of fadraciclib published in peer-reviewed journal shows specificity against CDK2 and CDK9 and enablement of apoptosis of cancer cells driven by MCL1, cyclin E and/or MYC – ...
RedHill Biopharma Announces Publication of Talicia® Pivotal Phase 3 Study Results in Annals of Internal Medicine
May 05, 2020 07:00 ET | RedHill Biopharma Ltd.
Talicia® is approved by the U.S. FDA and promoted by RedHill’s U.S. sales force--Abstract discussing Talicia pharmacokinetics and exposure-response presented as ePoster at Digestive Disease Week®...
Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology
April 29, 2020 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
These previously presented data demonstrated lenabasum improved efficacy outcomes and underlying disease pathology compared to placebo and had an acceptable safety profile in Phase 2 studySystemic...
2020-0227 Cognition Logo.jpg
Cognition Therapeutics Announces Publication Analyzing Biomarkers of Synapse Damage or Loss to Support Future Therapeutic Development Efforts in Alzheimer's Disease
March 17, 2020 08:03 ET | Cognition Therapeutics, Inc.
New York, March 17, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease...
RedHill Biopharma Announces Publication of RHB-102 Gastroenteritis Phase 3 Study Results in JAMA
November 12, 2019 07:00 ET | RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty...
Equillium_FullColor_RGB-300 - transparent.png
Equillium to Present New Data and Insights on the CD6-ALCAM Pathway in Lupus Nephritis at ACR 2019
November 06, 2019 08:05 ET | Equillium
LA JOLLA, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...